FilingSEC EDGAR10-K
Incannex Healthcare Files Fiscal 2026 Annual Report
· SEC accepted
StageClinical Stage
Filing content
The company updated the development status of its lead drug candidates, PSX-001 and IHL-42X, and is re-evaluating strategies for IHL-675A following the termination of its Australian Phase 2 trial.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…